BeiGene $ONC
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS8
PHASE 3 / 2-34
RECRUITING1
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO75%
Delay Index: of 8 active trials registered more than a year ago, 6 have moved their primary completion (readout) date by more than 6 months since first registration (median +8.8 months). See all sponsors →
Open BeiGene on the live radar map → 📅 $ONC readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| SEQUOIA NCT03336333 |
P3 | Active, not recruiting | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | 590 | 2021-05-07 (+8 mo) |
| Tislelizumab NCT04379635 |
P3 | Active, not recruiting | Non Small Cell Lung Cancer | 453 | 2023-08-21 (+7 mo) |
| BGB-11417 NCT05479994 |
P2 | Active, not recruiting | Leukemia; Lymphoma | 100 | 2025-01-24 (+4 mo) |
| Alcestobart NCT05609370 |
P1/2 | Active, not recruiting | Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | 113 | 2025-05-23 (+4 mo) |
| BGB-A445 NCT05661955 |
P1/2 | Active, not recruiting | Urothelial Carcinoma; Renal Cell Carcinoma | 113 | 2025-05-27 (+9 mo) |
| Pamiparib capsule NCT03519230 |
P3 | Active, not recruiting | Ovarian Cancer | 224 | 2025-12-01 (+68 mo) |
| Tislelizumab (BGB-A317) NCT03736889 |
P2 | Recruiting | MSI-H/dMMR Solid Tumors | 200 | 2026-11 (+59 mo) |
| Tislelizumab NCT03967977 |
P3 | Active, not recruiting | Urothelial Carcinoma | 420 | 2027-06-30 (+60 mo) |